By Mill Chart
Last update: Mar 21, 2024
Uncover the potential of GENMAB A/S -SP ADR (NASDAQ:GMAB), a growth stock that our stock screener found to be reasonably priced. NASDAQ:GMAB is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. We'll examine each aspect in detail.
A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:GMAB has received a 8 out of 10:
ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:GMAB was assigned a score of 6 for valuation:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:GMAB has achieved a 8 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:GMAB has achieved a 7:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
Our latest full fundamental report of GMAB contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
GENMAB A/S -SP ADR
NASDAQ:GMAB (4/19/2024, 7:00:00 PM)
After market: 28.7 0 (0%)28.7
+0.37 (+1.31%)
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Genmab is buying a privately held company focused on antibody drug conjugates.
Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.
BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term
Genmab reports a FY operating profit of DKK 5,321 million in 2023, with revenue reaching DKK 16.47B, driven by successful collaborations and strong product...
Pfizer (PFE) and Genmab (GMAB) announced on Friday the marketing application for its cervical cancer antibody-drug conjugate ((ADC)) has been validated for revi